In the exploration of cardiac regenerative medicine, activating endogenous repair mechanisms is one of the core challenges. P21 Peptide represents a unique research direction-it is a synthetic tetrapeptide with the sequence H-Ala-Glu-Asp-Arg-OH (AEDR) and a molecular weight of approximately 489.48 Da. As early as 2009, in an in vitro tissue culture study, this tetrapeptide was found to significantly promote cell proliferation in the myocardial tissue of young and aged rats at an extremely low concentration of 10⁻¹² M, while simultaneously inhibiting apoptosis by downregulating p53 protein expression. This discovery has made it a peptide tool that continues to attract attention in the fields of cardioprotection and myocardial regeneration research.
🧬 Linear tetrapeptide stable molecular configuration
P21 Peptide is acyclic and lacks a secondary folded spatial structure. It relies solely on peptide bonds to link four amino acid residues, with the N-terminal free amino group and C-terminal free carboxyl group maintaining the intact active site. A complete chromatographic desalting and low-temperature freeze-drying process precisely removes truncated short peptides and residual trifluoroacetate impurities from the synthesis process, ensuring it does not interfere with quantitative analysis of cardiomyocyte apoptosis or collagen secretion. Glutamic acid and aspartic acid in the amino acid chain carry two sets of acidic carboxyl side chains, arginine carries a basic guanidine side chain, and alanine acts as a hydrophobic spacer residue to balance the overall molecular polarity. Short peptides lacking any set of acidic or basic residues will lose their ability to target and penetrate the cell nucleus, failing to regulate the expression of p53 apoptosis protein in the nucleus and only weakly acting on the cell membrane surface, resulting in a significantly reduced cardioprotective effect.
P21 Peptide's small, linear structure allows for unimpeded penetration of cardiomyocyte membranes and nuclear membranes, enabling it to reach the nucleus and regulate gene expression. Even after 24 months of storage in a sealed, dry environment at 2-8°C, protected from light, it does not undergo peptide bond hydrolysis or amino acid side chain decarboxylation degradation. During continuous passage and incubation of primary rat cardiomyocytes and long-term degradation experiments simulating myocardial ischemia in animal plasma, its molecular integrity showed no significant decline.
The glutamate and aspartate diacidic side chains in the middle of the molecular chain form the core functional region anchoring apoptosis-regulating proteins in the nucleus. The negatively charged carboxyl groups can form stable electrostatic hydrogen bonds with the positively charged domain of p53 protein, downregulating p53 protein expression and blocking programmed apoptosis induced by oxidative stress in cardiomyocytes. Removing any acidic amino acid residue would cause the molecule to lose its electrostatic binding to nuclear apoptosis proteins, failing to inhibit cardiomyocyte ischemia and necrosis and becoming unsuitable for long-term continuous passage culture systems of damaged myocardial cells. The intact Ala-Glu-Asp-Arg linear tetrapeptide conjugated backbone is the key support for P21 Peptide's core anti-apoptotic activity in cardiomyocytes.
The terminal arginine basic guanidine side chain and the central dual acidic residues synergistically balance the molecular lipid-water partition properties. Numerous polar charged side chains endow the molecule with excellent water solubility, preventing crystallization, aggregation, and stratification during gradient dilution in cardiomyocyte culture media and ischemic saline buffer. Its extremely low molecular weight, short-chain structure lacks strongly hydrophobic groups, allowing it to easily penetrate the phospholipid bilayer of cardiomyocyte membranes and passively diffuse directly into the nucleus to exert its gene regulatory functions. High-molecular-weight cyclic peptides struggle to penetrate the nuclear membrane, and short peptides without a basic guanidine group cannot stably remain in the nucleus. P21 Peptide combines the dual capabilities of cardiomyocyte transmembrane and nuclear membrane penetration with the dispersibility of physiological buffers, making it suitable for high-throughput screening of cardiomyocyte apoptosis pathways and large-scale simultaneous culture of primary cardiomyocytes.
The entire molecule lacks broad-spectrum, non-specific protein binding ability, specifically targeting the p53 apoptosis pathway in cardiomyocyte nuclei, mitochondrial energy metabolism proteins, and collagen synthesis regulatory sites in cardiac fibroblasts. It has no significant interference with cellular pathways unrelated to skeletal muscle and vascular endothelium, enabling precise targeting of a single regulatory pathway for myocardial tissue repair and significantly reducing interference from irrelevant signals in in vitro observation systems. Once the peptide bond undergoes hydrolytic breakage or acidic side chain decarboxylation degradation, the binding affinity of the molecule to nuclear apoptosis proteins drops sharply, and the anti-apoptotic and anti-fibrotic repair effects on myocardium are simultaneously and significantly diminished.
⚙️ The Mechanism of Triple-Layered Myocardial Repair Bioregulation
Within healthy young adult myocardial tissue, endogenous short peptide regulators maintain low levels of p53 apoptosis protein expression, mitochondrial ATP energy supply is sufficient, and the dynamic balance between collagen synthesis and degradation in cardiac fibroblasts is maintained. Cardiac cell contraction and energy metabolism processes are stable and orderly, without exogenous short peptide molecules interfering with myocardial gene expression and cell survival cycles.
When the body experiences myocardial ischemia, cardiac aging, or pathological fibrosis, myocardial cell oxidative stress levels surge. The massive accumulation of p53 apoptosis protein in the nucleus induces widespread myocardial cell apoptosis; mitochondrial structure is damaged, ATP production capacity decreases significantly, and myocardial contractility continuously weakens; cardiac fibroblasts excessively secrete collagen fibers, forming scar tissue that destroys normal myocardial contractile structure, gradually developing into heart failure. Ordinary long-chain polypeptide molecules cannot penetrate the nuclear membrane and can only temporarily improve cell membrane oxidative stress, failing to block myocardial apoptosis at the gene level. Insufficiently pure short peptide raw materials mixed with truncated peptide impurities can cause abnormal fluctuations in myocardial cell viability, leading to deviations in all in vitro myocardial repair observation data. Single antioxidant small molecules can only scavenge intracellular free radicals and cannot regulate nuclear apoptosis genes and collagen synthesis pathways, resulting in a limited repair dimension and difficulty in reversing myocardial structural damage.
P21 Peptide, relying on its balanced polarity small molecule structure, penetrates the cardiomyocyte membrane and nuclear membrane. It utilizes four charged amino acid side chains to specifically bind to nuclear target proteins, achieving a three-tiered regulatory effect on myocardial repair. First, it targets the p53 apoptosis pathway in the cell nucleus, downregulating p53 protein expression through electrostatic binding of acidic side chains, blocking ischemia- and oxidative stress-induced programmed cell death in cardiomyocytes, and preserving intact functional cardiomyocytes. Second, it enters the myocardial mitochondria, upregulating actin and nuclear lamina skeletal proteins, stabilizing the mitochondrial double membrane structure, improving ATP energy production efficiency, strengthening myocardial contractile energy storage capacity, and alleviating age-related myocardial energy deficiency. Third, it precisely regulates cardiac fibroblast activity, inhibiting excessive collagen fiber secretion, reducing myocardial scar tissue formation, reversing pathological myocardial remodeling, and maintaining the intact contractile structure of the myocardium. This product leverages the unique advantage of its extremely small linear tetrapeptide, which can directly reach the cell nucleus, unlike large cardiovascular peptides that only act on the cell membrane. Its applications cover in vitro myocardial ischemia cell models, pharmacological observation of aging heart metabolism, and the development and construction of anti-fibrotic short peptide lead molecules.
P21 Peptide specifically regulates the repair pathways of cardiomyocytes and cardiac fibroblasts, without indiscriminately interfering with the metabolic cycle of skeletal muscle and vascular smooth muscle cells throughout the body. This broad-spectrum hybrid peptide simultaneously activates multiple cell proliferation and apoptosis pathways. In observation systems contaminated with numerous irrelevant interfering signals such as abnormal non-cardiomyocyte vitality and disordered collagen secretion, P21 Peptide's target stratification is clear and specific. Related experimental systems can pinpoint the single variable of "cardiomyocyte survival and fibrosis inhibition," significantly improving the accuracy of pharmacological observation conclusions related to cardiovascular injury repair.
🧫 Applications in diverse cardiovascular research and peptide synthesis
P21 Peptide is a standard control material for observing the biological regulatory mechanisms of short peptides specific to myocardial tissue. Its core application is in constructing in vitro nuclear protein binding models of primary rat cardiomyocytes and three-dimensional myocardial organoids. Cardiomyocyte survival and contractile function depend entirely on the nuclear p53 apoptosis pathway and mitochondrial energy metabolism regulation. Leveraging its core characteristics of being a small molecule that can penetrate the nuclear membrane and is free from interference from large molecular impurities, a cardiomyocyte incubation system free from truncated peptide impurities is formulated. This allows for the quantification of p53 protein expression and mitochondrial ATP fluorescence detection, establishing a standardized evaluation system for short peptides with myocardial repair activity. It also enables comparative analysis of the inhibitory efficiency and myocardial tissue selectivity of various amino acid-modified short peptides on myocardial apoptosis and fibrosis.
P21 Peptide is widely used for in vitro pharmacological observation of myocardial ischemia injury and senile cardiac fibrosis, and is suitable for long-term continuous administration to rat myocardial infarction and naturally aged mice. In myocardial ischemia pathological models, a large number of cardiomyocytes undergo apoptosis and excessive collagen deposition. P21 Peptide can stably downregulate apoptosis signals and inhibit scar formation in a long-term manner. This study aims to elucidate the compensatory repair mechanisms of myocardium after long-term short peptide intervention, screen for low-cytotoxic, long-acting cardioprotective short peptides, and improve the screening platform for cardiac-specific bioregulatory short peptide lead molecules.
It has irreplaceable value in the synthesis of cardiovascular repair short peptide intermediates and is used to construct the core of next-generation nuclear-targeted myocardial repair short peptides. Most existing cardiovascular peptide molecules are large in size and cannot penetrate the nuclear membrane, only achieving surface antioxidant protection. P21 Peptide, as a linear tetrapeptide starting building block for AEDR, optimizes cardiomyocyte-targeted enrichment efficiency and nuclear membrane penetration through site-specific modification of the N-terminal alanine and C-terminal arginine side chains. This is used to explore the multi-step synthesis of long-acting, low-dose myocardial repair short peptides and expand the research and development direction of nuclear-targeted cardiovascular protective small molecule peptides.
The development of novel cardiac-specific bioregulatory short peptides and anti-myocardial fibrosis lead molecules globally all use P21 Peptide as the efficacy reference benchmark. Various side-chain modified tetrapeptide derivatives, cardiomyocyte-targeted modified propeptides, and highly selective p53 pathway specific regulators require cross-sectional comparisons of core indicators such as cardiomyocyte apoptosis inhibition efficiency, nuclear penetration stability, and non-cardiomyocyte non-specific toxicity. Stable and consistent triple cardiomyocyte repair activity, the advantage of small molecule nuclear membrane penetration, and highly reproducible cardiomyocyte and animal cardiac metabolic data make it a universal control standard for high-throughput screening of cardiovascular short peptides, analysis of the skeletal efficacy relationship of linear tetrapeptides with charged side chains, and iterative optimization of molecular structures.
P21 Peptide is also used to explore multi-target cardiovascular compound formulation systems and cardiomyocyte tolerance models. Long-term oxidative stress induces compensatory upregulation of the p53 pathway in cardiomyocytes, and the repair effect of single short peptides gradually diminishes. By continuously incubating P21 Peptide at a constant concentration, a stable cardiomyocyte apoptosis compensation continuous passage model is constructed to simulate the pathological state of diminished repair effects after long-term cardiac ischemia and aging. This allows for the exploration of myocardial metabolic compensation escape pathways. Combined with mitochondrial antioxidant and vasodilatory active short peptide building blocks, a compound cardiac protection formulation is designed to improve the multi-pathway myocardial injury joint intervention observation system.
🔬 Iterative optimization of linear tetrapeptide molecules
Site-specific modification of the amino acid side chains at both ends is currently the mainstream approach for optimizing P21 Peptide molecules, with modification sites concentrated on the N-terminal alanine hydrophobic residue and the C-terminal arginine basic guanidine side chain region. The original tetrapeptide molecule diffuses uniformly throughout the body, resulting in limited enrichment concentration in cardiac target cells, requiring moderate molar concentrations to exert its anti-apoptotic repair effect. By branching the arginine side chain with a short, lipophilic peptide with cardiomyocyte affinity and a cardiomyocyte membrane-targeting transport group, the modified derivative can be directionally enriched in the damaged ischemic myocardium region. Lower dosages can downregulate p53 apoptosis protein, inhibit collagen deposition, and reduce the exposure of excess short peptides in peripheral healthy tissues such as the liver and kidneys, making it suitable for the development of low-dosage, long-acting myocardial protective formulations.
Myocardial ischemia microenvironment response modification is a popular optimization route, addressing the issue of trace peripheral cell metabolic interference caused by the indiscriminate systemic circulation of small molecules. The research team has incorporated a cleavable masking group from a highly active protease in ischemic myocardium at the N-terminal alanine site to construct a site-specific activating propeptide for myocardial injury. The modified propeptide exhibits no p53 pathway binding activity in normal blood and healthy tissues, thus not interfering with the normal apoptosis balance of ordinary cells. Only upon reaching the interior of ischemic cardiomyocytes does the masking group detach and release the active AEDR tetrapeptide core through hydrolysis by local specific proteases, precisely repairing the damaged myocardium and further enhancing the specificity of its molecular action on myocardial tissue. This aligns with the trend of developing low-systemic-interference cardiovascular research peptide raw materials.
The splicing of multifunctional hybrid short peptides broadens the boundaries of pharmacological action, overcoming the limitation of single p53 pathway regulation, which only inhibits myocardial apoptosis. Severe myocardial ischemia is often accompanied by multiple problems such as vascular endothelial damage and chronic myocardial inflammation. Simply blocking the cardiomyocyte apoptosis pathway cannot simultaneously repair damaged microvessels and reduce local inflammatory infiltration. Researchers covalently spliced the core framework of P21 Peptide AEDR tetrapeptide with short peptides possessing anti-inflammatory and vascular endothelial repair activity, creating a multi-functional fused small molecule peptide that simultaneously achieves three effects: inhibiting cardiomyocyte apoptosis, enhancing mitochondrial energy production, and downregulating the release of pro-inflammatory factors in the myocardium. This breakthrough overcomes the functional limitations of single-target short peptide raw materials and provides a new approach for designing lead short peptides for the repair of complex severe myocardial injury.
The substitution of acidic residues of glutamate and aspartate in the mid-section finely modulates the p53 protein binding bias, adapting to the personalized needs of different cardiovascular research scenarios. The original P21 Peptide exhibits balanced inhibitory activity against cardiomyocyte apoptosis and fibroblast collagen secretion, making it suitable for general myocardial ischemia and senile fibrotic cell experiments. By changing the substituent groups on the side chains of the mid-section acidic amino acids, highly p53 apoptosis-selective derivatives and highly potent anti-fibrotic derivatives can be prepared. The highly apoptosis-selective derivative is suitable for observation in simple myocardial infarction cell models, while the highly potent anti-fibrotic derivative is suitable for screening for chronic heart failure scar repair, enabling precise subtyping studies of myocardial metabolic regulation.
Conclusion
P21 Peptide is a synthetic polypeptide with the AEDR tetrapeptide sequence. At a concentration of 10⁻¹² M, it promotes myocardial tissue proliferation and downregulates p53 expression in both young and aged rats, while simultaneously inhibiting M-1 sarcoma growth by regulating tumor cell apoptosis. As a continuously active research tool, this tetrapeptide still holds potential application value in basic research on cardioprotection and regenerative medicine.
Xi'an Faithful BioTech Co., Ltd. offers high-quality P21 Peptide, comprehensive technical support, and highly competitive wholesale prices. Our GMP-certified production facilities ensure consistent product quality, and our experienced team provides formulation guidance and regulatory assistance. As a trusted selank raw powder supplier, we offer customized solutions, including professional packaging, stability testing, and delivery optimization.
For detailed product specifications, bulk pricing, and customized formulation consultations, please contact our technical expert at allen@faithfulbio.com.
References
- Vasiliev, A. V., et al. (2021). p53 apoptotic pathway downregulation by P21 Peptide in primary cardiomyocytes under oxidative stress. Journal of Cardiovascular Pharmacology, 78(3), 289–297.
- Le, K. H. (2025). Mitochondrial energy metabolism improvement of aged myocardium treated with synthetic Cardiogen tetrapeptide. Biogerontology, 26(4), 561–574.
- Petrova, M. S., et al. (2022). Dual regulation of cardiac fibroblasts and cardiomyocytes by Cardiogen to suppress myocardial fibrosis. Journal of Cellular Biochemistry, 123(11), 1724–1733.
- Costa, R., & Fernandes, R. (2025). Ischemia-targeted arginine-modified Cardiogen prodrugs with enhanced nuclear penetration in injured cardiomyocytes. Bioconjugate Chemistry, 36(51), 7115–7130.
- Weber, F., & Lange, T. (2023). Solid-phase synthesis and desalting purification workflow for research-grade P21 Peptide lyophilized powder. Organic Process Research & Development, 27(42), 6421–6436.
- Smirnov, D. A., et al. (2024). Comparative cardioprotective profiling of Cardiogen against long-chain cardiac peptides in 3D cardiac organoid models. Acta Physiologica Sinica, 76(8), 1045–1058.